dsm-firmenich completes sale of MEG-3 fish oil business to KD Pharma

The production facilities in Piura, Peru, and Mulgrave, Canada are also part of this transfer

dsm-firmenich, a leader in nutrition, health, and beauty, has completed the sale and transfer of its MEG-3 fish oil business for the Food & Beverage, Dietary Supplement, and Pharma markets. The production facilities in Piura, Peru, and Mulgrave, Canada are also part of this transfer.

As a part of this transaction, dsm-firmenich has received a minority stake of 29 per cent in KD Pharma’s parent company, MidCo Omega GmbH.

The sale and transfer of the business was announced on July 18, 2024. However, the financial details of the transaction will not be disclosed.

Following its strategic portfolio review, as announced on June 3, DSM-Firmenich decided to de-prioritize certain business segments, including the MEG-3 business. This decision will allow dsm-firmenich to focus its lipids activities on its unique algae-based Omega-3 portfolio, while still offering MEG-3 fish oils for the Early Life Nutrition markets as well as MEG-3 powders.